admin – Page 3589 – Get News Story

Atopic Keratoconjunctivitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Atopic Keratoconjuctivitis Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Atopic Keratoconjuctivitis pipeline landscape. It covers the Atopic Keratoconjunctivitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atopic Keratoconjunctivitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Atopic Keratoconjunctivitis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Atopic Keratoconjunctivitis Pipeline Outlook

Key Takeaways from the Atopic Keratoconjunctivitis Pipeline Report

DelveInsight’s Atopic Keratoconjunctivitis pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Atopic Keratoconjunctivitis treatment.
The leading Atopic Keratoconjunctivitis Companies such as Akari Therapeutics, Allakos, and others.
Promising Atopic Keratoconjunctivitis Pipeline Therapies such as Dupilumab, Cyclosporine 0.010% and others.

Stay ahead with the most recent pipeline outlook for Atopic Keratoconjunctivitis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Atopic Keratoconjunctivitis Treatment Drugs

Atopic Keratoconjunctivitis Emerging Drugs Profile

rVA576: Akari Therapeutics

rVA576 is currently in Phase I/II of clinical trial study and is being developed by Akari Therapeutics for the treatment of Atopic Keratoconjuctivitis. Thye trial got initiated in February 2019 and is expected to get completed by February 2022.

The Atopic Keratoconjunctivitis Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Atopic Keratoconjunctivitis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Keratoconjunctivitis Treatment.
Atopic Keratoconjunctivitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Atopic Keratoconjunctivitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Keratoconjunctivitis market

Explore groundbreaking therapies and clinical trials in the Atopic Keratoconjunctivitis Pipeline. Access DelveInsight’s detailed report now! @ New Atopic Keratoconjunctivitis Drugs

Atopic Keratoconjunctivitis Companies

Akari Therapeutics, Allakos, and others.

Atopic Keratoconjuctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravitreal
Subretinal
Topical.
Molecule Type

Atopic Keratoconjunctivitis Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Unveil the future of Atopic Keratoconjunctivitis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Atopic Keratoconjunctivitis Market Drivers and Barriers

Scope of the Atopic Keratoconjunctivitis Pipeline Report

Coverage- Global
Atopic Keratoconjunctivitis Companies- Akari Therapeutics, Allakos, and others.
Atopic Keratoconjunctivitis Pipeline Therapies- Dupilumab, Cyclosporine 0.010% and others.
Atopic Keratoconjunctivitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Atopic Keratoconjunctivitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Atopic Keratoconjunctivitis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Atopic Keratoconjunctivitis Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Atopic Keratoconjuctivitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Atopic Keratoconjuctivitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Atopic Keratoconjuctivitis Collaboration Deals
Late Stage Products (Phase III)
Drug Name: Company Name
Mid Stage Products (Phase I/II)
rVA576: Akari Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AK002: Allakos
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Atopic Keratoconjuctivitis Key Companies
Atopic Keratoconjuctivitis Key Products
Atopic Keratoconjuctivitis- Unmet Needs
Atopic Keratoconjuctivitis- Market Drivers and Barriers
Atopic Keratoconjuctivitis- Future Perspectives and Conclusion
Atopic Keratoconjuctivitis Analyst Views
Atopic Keratoconjuctivitis Key Companies
28. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Atopic Keratoconjunctivitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Phenylketonuria Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Phenylketonuria Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Phenylketonuria pipeline landscape. It covers the Phenylketonuria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Phenylketonuria pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Phenylketonuria Pipeline. Dive into DelveInsight’s comprehensive report today! @ Phenylketonuria Pipeline Outlook

Key Takeaways from the Phenylketonuria Pipeline Report

In March 2025, Sanofi announced a study is constituted of 2 separate parts: a dose escalation part, and a dose expansion part where subsequent participants will be administered a safe and effective dose level identified during the dose escalation part. In both study parts, clinical and laboratory assessments will be collected to: a) assess the incidence of adverse events, and b) evaluate the effect of SAR444836 on reductions in blood Phe levels and maintenance of these Phe levels after elimination of a Phe restricted diet.
In March 2025, PTC Therapeutics conducted a study includes 2 parts: Part 1 and 2. Part 1 is an open-label sepiapterin-responsiveness test, and Part 2 is an open-label treatment period.
DelveInsight’s Phenylketonuria pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Phenylketonuria treatment.
The leading Phenylketonuria Companies such as PTC Therapeutics, BioMarin Pharmaceutical, Otsuka Pharmaceutical, Relief Therapeutics Holding, BioMarin Pharmaceutical, Tessera Therapeutics and others.
Promising Phenylketonuria Pipeline Therapies such as Sepiapterin, PTC923, SYNB1618, SYNB1934, SAR444836, Kuvan®, Sapropterin dihydrochloride and others.

Stay ahead with the most recent pipeline outlook for Phenylketonuria. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Phenylketonuria Treatment Drugs

Phenylketonuria Emerging Drugs

Sepiapterin: PTC Therapeutics

Sepiapterin (formerly PTC923), an oral formulation of synthetic sepiapterin, has a dual mechanism of action to increase activity of the phenylalanine hydroxylase (PAH) enzyme. First, sepiapterin is a precursor compound that is rapidly absorbed and converted intracellularly to tetrahydrobiopterin (BH4), a critical cofactor of PAH. Sepiapterin also has an independent chaperone effect, protecting against PAH misfolding to enhance the enzyme function. Through this dual mechanism of action, sepiapterin effectively reduces blood phenylalanine (Phe) levels and has the potential to treat the broad range of PKU patients. Currently the drug is in been registered for Phenylketonuria (PKU).

JNT-517: Otsuka Pharmaceutical

JNT-517 is a selective small molecule inhibitor of the Phe transporter SLC6A19 that has the potential to be a first-in-class oral therapy used to treat any person with PKU, regardless of age or genotype. JNT-517 acts at a novel, cryptic allosteric site to block kidney reabsorption of Phe and offers a promising new approach to reduce blood. . Currently the drug is in Phase III for Phenylketonuria (PKU).

RLF OD032: Relief Therapeutics Holding

RLF-OD032, an innovative and highly concentrated liquid formulation of sapropterin dihydrochloride, is designed to lower blood phenylalanine in adult and pediatric PKU patients. It offers a more patient-friendly solution by significantly reducing the volume of medication required compared to current formulations. This advancement aims to enhance compliance, particularly among pediatric patients, who often struggle with the high volumes associated with existing sapropterin treatments. If approved, RLF-OD032 would be the first and only portable, ready-to-use liquid formulation of sapropterin dihydrochloride. Currently the drug is in Phase I Stage of its development for the treatment of Phenylketonuria (PKU).

The Phenylketonuria Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Phenylketonuria with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Phenylketonuria Treatment.
Phenylketonuria Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Phenylketonuria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Phenylketonuria market

Explore groundbreaking therapies and clinical trials in the Phenylketonuria Pipeline. Access DelveInsight’s detailed report now! @ New Phenylketonuria Drugs

Phenylketonuria Companies

PTC Therapeutics, BioMarin Pharmaceutical, Otsuka Pharmaceutical, Relief Therapeutics Holding, BioMarin Pharmaceutical, Tessera Therapeutics and others.

Phenylketonuria Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Phenylketonuria Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Unveil the future of Phenylketonuria Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Phenylketonuria Market Drivers and Barriers

Scope of the Phenylketonuria Pipeline Report

Coverage- Global
Phenylketonuria Companies- PTC Therapeutics, BioMarin Pharmaceutical, Otsuka Pharmaceutical, Relief Therapeutics Holding, BioMarin Pharmaceutical, Tessera Therapeutics and others.
Phenylketonuria Pipeline Therapies- Sepiapterin, PTC923, SYNB1618, SYNB1934, SAR444836, Kuvan®, Sapropterin dihydrochloride and others.
Phenylketonuria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Phenylketonuria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Phenylketonuria Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Phenylketonuria Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Phenylketonuria: Overview
Pipeline Therapeutics
Therapeutic Assessment
Phenylketonuria– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
JNT-517: Otsuka Pharmaceutical
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug Name: Company Name
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
RLF OD032: Relief Therapeutics Holding
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name : Company name
Drug profiles in the detailed report…..
Inactive Products
Phenylketonuria Key Companies
Phenylketonuria Key Products
Phenylketonuria- Unmet Needs
Phenylketonuria- Market Drivers and Barriers
Phenylketonuria- Future Perspectives and Conclusion
Phenylketonuria Analyst Views
Phenylketonuria Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Phenylketonuria Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Vernal Keratoconjunctivitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Vernal Keratoconjunctivitis Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Vernal Keratoconjunctivitis pipeline landscape. It covers the Vernal Keratoconjunctivitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Vernal Keratoconjunctivitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Vernal Keratoconjunctivitis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Vernal Keratoconjunctivitis Pipeline Outlook

Key Takeaways from the Vernal Keratoconjunctivitis Pipeline Report

DelveInsight’s Vernal Keratoconjunctivitis pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Vernal Keratoconjunctivitis treatment.
The leading Vernal Keratoconjunctivitis Companies such as iCo Therapeutics, Vanda Pharmaceuticals, Sylentis, Allakos and others.
Promising Vernal Keratoconjunctivitis Pipeline Therapies such as Cyclosporine A, Dexamethasone, FK506 and others.

Stay ahead with the most recent pipeline outlook for Vernal Keratoconjunctivitis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Vernal Keratoconjunctivitis Treatment Drugs

Vernal Keratoconjunctivitis Emerging Drugs Profile

iCo-008: iCo Therapeutics

Bertilimumab is a fully human monoclonal antibody with specificity for human eotaxin-1 and inhibits its function. Favourable results from pre-clinical assessments resulted in three clinical studies of bertilimumab conducted in EU (a total of 126 patients – healthy individuals, patients with a history of seasonal allergic rhinitis and individuals with a history of seasonal allergic conjunctivitis) provided evidence of good safety and tolerability of bertilimumab when administered by the intravenous (IV) or intranasal route as well as topical application to the eye. A Phase II clinical trial for patients with vernal keratoconjunctivitis and/or atopic keratoconjunctivitis (involving cornea and conjunctiva) is in preparation.

The Vernal Keratoconjunctivitis Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Vernal Keratoconjunctivitis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vernal Keratoconjunctivitis Treatment.
Vernal Keratoconjunctivitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Vernal Keratoconjunctivitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vernal Keratoconjunctivitis market

Explore groundbreaking therapies and clinical trials in the Vernal Keratoconjunctivitis Pipeline. Access DelveInsight’s detailed report now! @ New Vernal Keratoconjunctivitis Drugs

Vernal Keratoconjunctivitis Companies

iCo Therapeutics, Vanda Pharmaceuticals, Sylentis, Allakos and others.

Vernal Keratoconjunctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical
Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Unveil the future of Vernal Keratoconjunctivitis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Vernal Keratoconjunctivitis Market Drivers and Barriers

Scope of the Vernal Keratoconjunctivitis Pipeline Report

Coverage- Global
Vernal Keratoconjunctivitis Companies- iCo Therapeutics, Vanda Pharmaceuticals, Sylentis, Allakos and others.
Vernal Keratoconjunctivitis Pipeline Therapies- Cyclosporine A, Dexamethasone, FK506 and others.
Vernal Keratoconjunctivitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Vernal Keratoconjunctivitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Vernal Keratoconjunctivitis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Vernal Keratoconjunctivitis Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Vernal Keratoconjunctivitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Drug Name: Company Name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Co-008: iCo Therapeutics
Drug profiles in the detailed report…..
Early stage products (Phase I)
AK002: Allakos
Drug profiles in the detailed report…..
Inactive Products
Vernal Keratoconjunctivitis Key Companies
Vernal Keratoconjunctivitis Key Products
Vernal Keratoconjunctivitis- Unmet Needs
Vernal Keratoconjunctivitis- Market Drivers and Barriers
Vernal Keratoconjunctivitis- Future Perspectives and Conclusion
Vernal Keratoconjunctivitis Analyst Views
Vernal Keratoconjunctivitis Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Vernal Keratoconjunctivitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Major Depressive Disorder Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Major Depressive Disorder Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Major Depressive Disorder pipeline landscape. It covers the Major Depressive Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Major Depressive Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Major Depressive Disorder Pipeline. Dive into DelveInsight’s comprehensive report today! @ Major Depressive Disorder Pipeline Outlook

Key Takeaways from the Major Depressive Disorder Pipeline Report

In April 2025, Cybin IRL Limited announced a study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
In April 2025, Janssen Research & Development LLC conducted a study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor [SSRI] or serotonin and norepinephrine reuptake inhibitor [SNRI]) in all participants with major depressive disorder (MDD).
DelveInsight’s Major Depressive Disorder pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Major Depressive Disorder treatment.
The leading Major Depressive Disorder Companies such as GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others.
Promising Major Depressive Disorder Pipeline Therapies such as NMRA-335140 Aticaprant, NBI-1065845, CYB003, Azetukalner, GW679769, BHV-7000 and others.

Stay ahead with the most recent pipeline outlook for Major Depressive Disorder. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Major Depressive Disorder Treatment Drugs

Major Depressive Disorder Emerging Drugs Profile

SAGE-217: Sage Therapeutics

SAGE-217 is an investigational, oral, novel medicine in development for depression. SAGE-217 is an investigational oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM). The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), and contributes significantly to regulating CNS function. Biogen and Sage Therapeutics have submitted a new drug application (NDA) to the FDA for zuranolone for the treatment of major depressive disorder (MDD).

REL-1017: Relmada Therapeutics Inc.

REL-1017, an NCE and novel NMDAR channel blocker with a preference for hyperactive channels associated with MDD. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for REL-1017 as an adjunctive treatment of MDD. REL-1017, has entered its Phase 3 registration program as an adjunctive treatment for MDD.

Seltorexant: Minerva Sciences

Seltorexant is an innovative selective orexin 2 receptor antagonist under development for the treatment of insomnia and related mood disorders. Insomnia is the repeated difficulty with sleep initiation, maintenance or quality that occurs despite adequate time and opportunity for sleep, resulting in daytime impairment. The clinical trials are being carried out for the treatment of major depressive disorder in phase III stage of development.

SP-624: Sirtsei Pharmaceuticals, Inc.

SP-624 is being studied in phase II stage of development for the treatment of major depressive disorder in comparison with placebo by Sirtsei Pharmaceuticals, Inc.

SPL026: Small Pharma

SPL026 (DMT), is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects. DMT is differentiated by its short psychedelic experience (< 30mins), which allows for short treatment sessions and offers the potential for convenient supervised treatments within patient clinics. Small Pharma is advancing a pipeline of DMT-based therapies and is leading the world’s first DMT clinical trial for depression, in collaboration with Imperial College London.

PDC-1421: BioLite Inc.

PDC-1421 (BLI-1005) is a Norepinephrine plasma membrane transport protein inhibitor being developed by BioLite Inc, for the treatment of major depressive disorder. The drug is currently in phase II stage of development.

The Major Depressive Disorder Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Major Depressive Disorder with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Major Depressive Disorder Treatment.
Major Depressive Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Major Depressive Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Major Depressive Disorder market

Explore groundbreaking therapies and clinical trials in the Major Depressive Disorder Pipeline. Access DelveInsight’s detailed report now! @ New Major Depressive Disorder Drugs

Major Depressive Disorder Companies

GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others.

Major Depressive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Subcutaneous
Intravenous
Intramuscular

Major Depressive Disorder Products have been categorized under various Molecule types such as

Bispecific Antibody
Peptides
Small molecule
Gene therapy

Unveil the future of Major Depressive Disorder Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Major Depressive Disorder Market Drivers and Barriers

Scope of the Major Depressive Disorder Pipeline Report

Coverage- Global
Major Depressive Disorder Companies- GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others.
Major Depressive Disorder Pipeline Therapies- NMRA-335140 Aticaprant, NBI-1065845, CYB003, Azetukalner, GW679769, BHV-7000 and others.
Major Depressive Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Major Depressive Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Major Depressive Disorder Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Major Depressive Disorder Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Major Depressive Disorder: Overview
Pipeline Therapeutics
Therapeutic Assessment
Major Depressive Disorder – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
SAGE-217: Sage Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
SP-624: Sirtsei Pharmaceuticals, Inc.
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
SPL026: Small Pharma
Drug profiles in the detailed report…..
Preclinical Stage Products
Drug Name: Company name
Drug profiles in the detailed report…..
Inactive Products
Major Depressive Disorder Key Companies
Major Depressive Disorder Key Products
Major Depressive Disorder- Unmet Needs
Major Depressive Disorder- Market Drivers and Barriers
Major Depressive Disorder- Future Perspectives and Conclusion
Major Depressive Disorder Analyst Views
Major Depressive Disorder Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Major Depressive Disorder Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Aspergillosis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Aspergillosis Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Aspergillosis pipeline landscape. It covers the Aspergillosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Aspergillosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Aspergillosis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Aspergillosis Pipeline Outlook

Key Takeaways from the Aspergillosis Pipeline Report

DelveInsight’s Aspergillosis pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Aspergillosis treatment.
The leading Aspergillosis Companies such as Regeneron/Sanofi, Pulmocide, Astellas Pharma, Cipla/Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF Pharmaceuticals, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, ImmuPharma, Takis and others.
Promising Aspergillosis Pipeline Therapies such as Voriconazole, Anidulafungin, VER002, FK463, MK0991, voriconazole, and others.

Stay ahead with the most recent pipeline outlook for Aspergillosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Aspergillosis Treatment Drugs

Aspergillosis Emerging Drugs Profile

PC945: Pulmocide

PC945 is a potent, long-acting antifungal triazole, possesses activity against a broad range of both azole-susceptible and azole-resistant strains of Aspergillus fumigatus. PC945 is being developed as an inhaled treatment for pulmonary aspergillosis. It has been designed to deliver high local lung concentrations, retention in lung tissues that offers a long duration of action and minimal systemic exposure.

Dupilumab: Regeneron/Sanofi

Dupilumab (Dupixent) is an interleukin-4 (IL-4) receptor alpha antagonist. It is a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits IL-4 and interleukin-13 (IL-13) signaling by specifically binding to the IL-4 receptor alpha subunit. Dupilumab is currently being studied in Phase III developmental studies for the treatment of patients with Allergic Bronchopulmonary Aspergillosis.

The Aspergillosis Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Aspergillosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Aspergillosis Treatment.
Aspergillosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Aspergillosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Aspergillosis market

Explore groundbreaking therapies and clinical trials in the Aspergillosis Pipeline. Access DelveInsight’s detailed report now! @ New Aspergillosis Drugs

Aspergillosis Companies

Regeneron/Sanofi, Pulmocide, Astellas Pharma, Cipla/Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF Pharmaceuticals, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, ImmuPharma, Takis and others

Aspergillosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravitreal
Subretinal
Topical
Molecule Type

Aspergillosis Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Unveil the future of Aspergillosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Aspergillosis Market Drivers and Barriers

Scope of the Aspergillosis Market Report

Coverage- Global
Aspergillosis Companies- Regeneron/Sanofi, Pulmocide, Astellas Pharma, Cipla/Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF Pharmaceuticals, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, ImmuPharma, Takis and others.
Aspergillosis Pipeline Therapies- Voriconazole, Anidulafungin, VER002, FK463, MK0991, voriconazole, and others.
Aspergillosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Aspergillosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Aspergillosis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Aspergillosis Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Aspergillosis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Aspergillosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Aspergillosis Collaboration Deals
Late Stage Products (Phase III)
Dupilumab: Regeneron Pharmaceuticals/Sanofi
Mid Stage Products (Phase II)
Ibrexafungerp: Scynexis
PC945: Pulmocide
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
TFF VORI: TFF Pharmaceuticals
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
MAT2203: Matinas BioPharma
Inactive Products
Aspergillosis Key Companies
Aspergillosis Key Products
Aspergillosis- Unmet Needs
Aspergillosis- Market Drivers and Barriers
Aspergillosis- Future Perspectives and Conclusion
Aspergillosis Analyst Views
Aspergillosis Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Aspergillosis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Respiratory Syncytial Virus Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Respiratory Syncytial Virus Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Respiratory Syncytial Virus (RSV) pipeline landscape. It covers the Respiratory Syncytial Virus pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Respiratory Syncytial Virus pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Respiratory Syncytial Virus Pipeline. Dive into DelveInsight’s comprehensive report today! @ Respiratory Syncytial Virus Pipeline Outlook

Key Takeaways from Respiratory Syncytial Virus Pipeline Report

DelveInsight’s Respiratory Syncytial Virus pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Respiratory Syncytial Virus treatment.
The leading Respiratory Syncytial Virus Companies such as AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.
Promising Respiratory Syncytial Virus Pipeline Therapies such as JNJ-53718678 2.5 mg/kg, Clesrovimab, RSV-A Memphis 37b, Matrix-M1 Adjuvant and others.

Stay ahead with the most recent pipeline outlook for Respiratory Syncytial Virus. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Respiratory Syncytial Virus Treatment Drugs

Respiratory Syncytial Virus Emerging Drugs Profile

Clesrovimab: Merck Sharp & Dohme

Clesrovimab (MK-1654) is an investigational extended half-life monoclonal antibody (mAb) developed as a passive immunization for the prevention of RSV-associated medically attended lower respiratory infection (MALRI). Clesrovimab is being studied in infants (pre-term and full-term) to provide rapid, durable protection through their first RSV season with a single, fixed-dose administration. Currently, the drug is in the Phase III stage of its development for the treatment of Respiratory Syncytial Virus (RSV).

IVX A12: AstraZeneca

IVX-A12 is a potential bivalent first-in-class combination vaccine candidate containing VLPs that incorporate stabilized prefusion F proteins from RSV and hMPV viruses. The FDA has granted IVX-A12 Fast Track designation in adults ≥60 years of age. IVX-A12 is a liquid, refrigerator-stable formulation comprised of IVX-121, Icosavax’s RSV prefusion F protein VLP vaccine candidate. Phase II data demonstrate that IVX-A12 elicits robust immune responses against both RSV and hMPV one month after vaccination and reconfirm previous immunogenicity data seen in the Phase I trial. The data are the first to demonstrate hMPV immune response in a Phase II combination vaccine trial. Currently, the drug is in the Phase II stage of its development for the treatment of Respiratory Syncytial Virus (RSV).

MV-012-968: Meissa Vaccines, Inc

MV-012-968, an intranasal (needle-free), adjuvant-free, live attenuated vaccine candidate, to protect infants from RSV. MV-012-968 is well-tolerated, highly attenuated, and induces a strong systemic and mucosal IgA antibody response in RSV-naïve children. Meissa is currently enrolling participants between the ages of six and 36 months in a Phase Ic clinical study at multiple sites in the U.S. to evaluate the safety and immunogenicity of MV-012-968. MV-012-968 was generated using the company’s proprietary AttenuBlockTM synthetic biology platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines. Currently, the drug is in the Phase I stage of its development for the treatment of Respiratory Syncytial Virus (RSV).

The Respiratory Syncytial Virus Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Respiratory Syncytial Virus with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Respiratory Syncytial Virus Treatment.
Respiratory Syncytial Virus Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Respiratory Syncytial Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Respiratory Syncytial Virus market

Explore groundbreaking therapies and clinical trials in the Respiratory Syncytial Virus Pipeline. Access DelveInsight’s detailed report now! @ New Respiratory Syncytial Virus Drugs

Respiratory Syncytial Virus Companies

AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.

Respiratory Syncytial Virus (RSV) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Molecule Type

Respiratory Syncytial Virus Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Unveil the future of Respiratory Syncytial Virus Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Respiratory Syncytial Virus Market Drivers and Barriers

Scope of the Respiratory Syncytial Virus Pipeline Report

Coverage- Global
Respiratory Syncytial Virus Companies- AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.
Respiratory Syncytial Virus Pipeline Therapies- JNJ-53718678 2.5 mg/kg, Clesrovimab, RSV-A Memphis 37b, Matrix-M1 Adjuvant and others.
Respiratory Syncytial Virus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Respiratory Syncytial Virus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Respiratory Syncytial Virus Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Respiratory Syncytial Virus Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Respiratory Syncytial Virus (RSV): Overview
Pipeline Therapeutics
Therapeutic Assessment
Respiratory Syncytial Virus (RSV) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Respiratory Syncytial Virus (RSV) Collaboration Deals
Late Stage Products (Phase III)
Clesrovimab: Merck Sharp & Dohme
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
IVX A12: AstraZeneca
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
MV-012-968: Meissa Vaccines, Inc
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Respiratory Syncytial Virus (RSV) Key Companies
Respiratory Syncytial Virus (RSV) Key Products
Respiratory Syncytial Virus (RSV)- Unmet Needs
Respiratory Syncytial Virus (RSV)- Market Drivers and Barriers
Respiratory Syncytial Virus (RSV)- Future Perspectives and Conclusion
Respiratory Syncytial Virus (RSV) Analyst Views
Respiratory Syncytial Virus (RSV) Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Respiratory Syncytial Virus Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

In-Depth Industry Outlook: Professional Street Sweeper Market Aims to Reach $3.70 Billion by 2030 – Arizton

“Professional Street Sweeper Market Research Report by Arizton”

According to Arizton’s latest research report, the global professional street sweeper market is growing at a CAGR of 6.06% during 2024-2030.

Looking for More Information? Click: https://www.arizton.com/market-reports/professional-street-sweeper-market

Report Scope:          

Market Size (2030): $3.70 Billion

Market Size (2024): $2.60 Billion

CAGR (2024-2030): 6.06%

Historic Year: 2021-2023

Base Year: 2024

Forecast Year: 2025-2030

Market Segmentation: Product Type, Capacity, Power Source, End Users, and Geography

Geographical Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa

Professional Street Sweepers Market Overview

The Professional Street Sweepers Market is experiencing steady growth, driven by increasing urbanization, industrial development, and the rising demand for cleaner, safer public spaces. As cities expand, the need for efficient, high-capacity street sweepers has grown to manage higher foot traffic, increased vehicular movement, and rising levels of dust and debris. Street sweepers are also essential in managing post-construction residue from infrastructure projects, such as metro systems, smart cities, and industrial zones.

Industries like cement, mining, and manufacturing also contribute to the demand for industrial-grade sweepers to maintain cleanliness and ensure safety on sites. Additionally, commercial areas like shopping malls and business parks rely on sweepers to uphold cleanliness and customer satisfaction.

The market is further bolstered by innovations in energy-efficient models, such as electric and hybrid sweepers, and a growing focus on sustainability. With rising government regulations on hygiene and air quality, the market is expected to continue expanding globally, supporting the development of smart cities and cleaner urban environments.

Top Segments Booming in the Global Professional Street Sweeper Market

Mechanical Street Sweepers Segment – Market Revenue & Forecast

Mechanical street sweepers remain a core segment in the Professional Street Sweepers market, particularly favored by municipalities and contractors for their durability, simplicity, and cost-effectiveness. These machines, utilizing rotating brushes and powerful suction systems, are essential for clearing debris, gravel, leaves, and waste across high-traffic urban areas, parking lots, airports, ports, and construction sites.

Despite being traditional in design, mechanical sweepers have evolved with improvements in fuel efficiency, dust suppression, and operator comfort, making them an ideal solution for heavy-duty cleaning tasks such as post-construction cleanup and event management. Municipalities in North America and Europe continue to invest in mechanical sweepers as part of urban sanitation programs, with cities like Chicago, Paris, and New Delhi expanding their fleets in 2024 to meet rising hygiene standards. Furthermore, infrastructure and construction projects, such as India’s Smart Cities Mission and the U.S. Infrastructure Investment and Jobs Act, have significantly driven the adoption of mechanical sweepers for post-construction cleaning.

Robotic and Automated Sweepers Segment – Market Revenue & Forecast

The robotic and automated sweepers segment is rapidly growing, driven by the expansion of smart city initiatives in both developed and developing countries. These advanced machines, equipped with sensors, cameras, and AI algorithms, can perform routine cleaning tasks autonomously, navigating urban environments, detecting debris, and adapting to different conditions. Ideal for 24/7 operations, they are increasingly used in city streets, airports, campuses, and industrial complexes.

Leveraging artificial intelligence and machine learning, robotic sweepers continuously optimize their cleaning routes, improve debris detection, and adjust cleaning intensity. This reduces the reliance on manual labor, offering long-term cost savings, consistent performance, and minimized operational risks. Additionally, electric-powered robotic sweepers contribute to environmental sustainability by reducing air and noise pollution, making them suitable for noise-sensitive areas. As cities focus on greener urban maintenance solutions, the demand for these automated systems is expected to rise, aligning with global sustainability goals and regulatory standards.

Professional Street Sweepers Market Competition and Growth

The professional street sweepers market is highly competitive, with global players like Tennant Company, Alfred Kärcher, Bucher Industries, Schwarze Industries, and Dulevo leading through innovation and sustainability. The demand for eco-friendly, IoT-enabled, and autonomous sweepers is growing, particularly in North America, APAC, and Europe. While established players invest in advanced technologies like AI and electric sweepers, regional vendors face challenges from low-cost alternatives, increasing market fragmentation. As digital transformation and automation reshape the industry, global expansion, particularly in emerging markets, will be key for vendors to maintain market leadership and competitiveness.

North American Professional Street Sweepers Market Growth

In 2023, the U.S. Infrastructure Investment and Jobs Act allocated $15 billion to environmental projects, including electric street sweepers in cities like Denver and Seattle. Similarly, Canada’s “Clean Streets for Healthy Cities” program will invest CAD $750 million by 2025 to promote low-emission sweeping fleets. North American municipalities are also adopting smart technologies, such as Austin’s GPS and AI-integrated fleet management system and San Diego’s trial of autonomous sweepers, improving efficiency and reducing operational costs. Private-sector expansions, like Amazon’s new fulfillment centers and Walmart Canada’s logistics hubs, are further driving the demand for professional street sweepers.

Looking for More Information? Click: https://www.arizton.com/market-reports/professional-street-sweeper-market

Key Company Profiles

Tennant Company
Alfred Kärcher SE & Co. KG
Global Environmental Products, Inc.
Bucher Municipal
Fayat Group
Aebi Schmidt Group
Piquersa Maquinaria, S.A.
Nilfisk A/S
Hako Machines Ltd
Çeksan Sweepers
Schwarze Industries
Alamo Group Inc.
Fulongma Group Co., Ltd.
TYMCO, Inc.
Madvac
Dulevo International S.p.A.
Eureka
FAUN Umwelttechnik GmbH & Co. KG
Green Machines International B.V.
Chengli Special Automobile Co., Ltd.
Zhengzhou Dongfeng Mid-South Enterprise Co., Ltd.
OMM Lavapavimenti
PowerBoss
Cleanland (Tirth Hygiene Technology Pvt. Ltd.)
Broce Broom
Victory Sweepers
Curbtender Sweepers
Sajas Group
FCC Group
NiteHawk Sweepers
Boschung

Market Segmentation

Product Type

Mechanical Street Sweepers
Regenerative Air Sweepers
Vacuum Sweepers
Robotic And Automated Sweepers
High-Efficiency Dustless Sweepers
Waterless Sweepers
Others

Capacity

Small Hopper Capacity
Medium Hopper Capacity
Large Hopper Capacity
Others

Power Source

Electric-Powered Sweepers
Gas-Powered Sweepers
Hybrid-Powered Sweepers
Hydrogen Fuel Cell Powered Sweepers
Others

End Users

Commercial Spaces
Municipality and City Governments
Industrial Facilities
Others

Geography

North America

The U.S.
Canada

Europe

Germany
France
Russia
The U.K.
Norway
Denmark
Italy
Poland
Spain

APAC

China
India
Japan
South Korea
Australia
Indonesia
Malaysia

Latin America

Brazil
Argentina
Mexico

Middle East & Africa

Saudi Arabia
UAE
South Africa

The Arizton Advisory & Intelligence market research report provides valuable market insights for industry stakeholders, investors, researchers, consultants, and business strategists aiming to gain a thorough understanding of the professional street sweeper market. Request for Free Sample to get a glance of the report now: https://www.arizton.com/market-reports/professional-street-sweeper-market

What Key Findings Will Our Research Analysis Reveal?        

How big is the global professional street sweeper market?

Which region dominates the global professional street sweeper market share?

What are the significant trends in the professional street sweeper market?

Who are the key players in the global professional street sweeper market?

Other Related Reports that Might be of Your Business Requirement    

U.S. Pool Maintenance & Cleaning Services Market – Focused Insights 2024-2029

https://www.arizton.com/market-reports/us-pool-maintenance-and-cleaning-services-market

Commercial Scrubbers and Sweepers Market – Global Outlook & Forecast 2024-2029

https://www.arizton.com/market-reports/commercial-scrubbers-sweepers-market-report-2025   

Why Arizton?

100% Customer Satisfaction

24×7 availability – we are always there when you need us

200+ Fortune 500 Companies trust Arizton’s report

80% of our reports are exclusive and first in the industry                      

100% more data and analysis

1500+ reports published till date

Post-Purchase Benefit                                               

1hr of free analyst discussion
10% off on customization

About Us:                                                                                        

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/professional-street-sweeper-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: In-Depth Industry Outlook: Professional Street Sweeper Market Aims to Reach $3.70 Billion by 2030 – Arizton

Geospatial Artificial Intelligence Market Revenue Expected to Double – Reaching $64.6 Billion by 2030 – Arizton

“Geospatial Artificial Intelligence Market Research Report by Arizton”

According to Arizton’s latest research report, the geospatial artificial intelligence market is growing at a CAGR of 9.25% during 2024-2030.

Looking for More Information? Click: https://www.arizton.com/market-reports/geospatial-artificial-intelligence-market

Report Scope:       

Market Size (2030): USD 64.60 Billion   

Market Size (2024): USD 38 Billion  

CAGR (2024-2030): 9.25%  

Historic Year: 2021-2023   

Base Year: 2024   

Forecast Year: 2025-2030  

Rapid Growth of the Geospatial AI (GeoAI) Market

The Geospatial AI (GeoAI) market is expanding rapidly, fueled by technological advancements, environmental challenges, and shifting consumer demands. GeoAI integrates AI technologies like machine learning with geographic data from satellites and maps to provide real-time insights for better decision-making. In 2024, the USGS collaborated with Esri and NASA to launch GeoAI tools for tracking wildfires and land changes, encouraging further public and private investment.

Industry leaders such as Hexagon AB and Airbus have developed sector-specific GeoAI tools, including mining dashboards and real-time deforestation monitors. Esri enhanced its ArcGIS Urban tool with AI features to help urban planners simulate city development. Businesses are also leveraging GeoAI—Orbital Insight helped a U.S. retailer boost store performance by 22% through foot traffic analysis.

GeoAI’s growing applications in emergency response, urban planning, retail, and environmental monitoring are driving its importance across industries. With ongoing innovation and rising adoption, the market is set for strong growth in 2025 and beyond.

Cloud-Based Deployment Gaining Momentum in the GeoAI Market

Cloud-based deployment is rapidly gaining traction in the Geospatial AI (GeoAI) market due to its scalability, lower upfront costs, and global accessibility. These solutions allow users to process and analyze vast amounts of spatial data without the need for extensive on-premises infrastructure. Leveraging distributed computing, cloud platforms support real-time analytics, satellite image processing, and predictive modeling, making them ideal for applications in government, urban planning, environmental monitoring, logistics, defense, and agriculture.

The integration of machine learning and deep learning algorithms enhances capabilities such as object detection, land classification, and disaster response. As satellite and IoT data availability increases, cloud-native AI tools offer greater flexibility, speed, and cost efficiency. Additionally, cloud deployment fosters seamless collaboration across teams and geographies—critical for large-scale geospatial projects—further cementing its role as a preferred choice for modern GeoAI applications.

Competitive Landscape and Future Outlook of the GeoAI Market

The GeoAI market is moderately concentrated, with increasing competition among global tech giants, regional players, and startups. Demand from sectors such as urban planning, defense, and agriculture is driving innovation in AI-powered spatial tools. Leaders like Esri, Google, and Trimble leverage advanced analytics and global reach, while regional vendors focus on specialized solutions and strong support to stay competitive.

Although AI advancements and open-source data have lowered entry barriers, they also risk market fragmentation. An influx of startups—some lacking in domain expertise or data validation—could lead to unreliable models, particularly in critical fields like disaster response or defense, impacting user trust.

Looking ahead, the market is moving toward next-gen technologies such as edge computing, AI-enhanced satellite sensing, and cloud-native platforms. Companies are prioritizing scalable, real-time, and automated geospatial solutions, with Esri and Google making efforts to build intelligent, integrated GeoAI ecosystems.

Book the Free Sample Now: https://www.arizton.com/market-reports/geospatial-artificial-intelligence-market

GeoAI Market Companies

Esri
Hexagon AB
Maxar Technologies
Google LLC (Alphabet Inc.)
Microsoft Corporation
IBM
Trimble Inc.
Autodesk, Inc.
Bentley Systems, Incorporated
Amazon Web Services, Inc. (AWS)
Airbus
Planet Labs PBC
Orbital Insight, Inc.
Descartes Labs, Inc.
Satellogic Inc.
Palantir Technologies Inc.
Blue Sky Analytics
Sparkgeo
GeoIQ
1Spatial
Agronomeye
AiDash
Alcis Holdings Ltd.
Anditi
ASTERRA
Atlas AI P.B.C.
Mapbox, Inc.
TomTom
HERE Technologies
CARTO
L3Harris Technologies, Inc.
TerraGo
Blue Marble Geographics
Northrop Grumman Corporation

Market Segmentation

Deployment Mode

Cloud-based
On-premises

Data Model

Vector Data
Raster Data
Others

Component

Software
Hardware
Services

Technology

Machine Learning
Computer Vision
Big Data Analytics
Deep Learning (DL)
Natural Language Processing (NLP)
Others

End Users

Enterprise
Individual

Enterprise

Government & Public Sector
Agriculture & Forestry
Energy & Utilities
Transportation & Logistics
Defense & Security
Others

Geography

North America

The U.S.
Canada

Europe

The U.K.
Germany
France
Russia
Spain
Italy
Denmark
Norway
Poland

APAC

China
India
Japan
South Korea
Australia
Singapore
Malaysia

Latin America

Brazil
Mexico
Argentina

Middle East & Africa

Saudi Arabia
The UAE
South Africa

The Arizton Advisory & Intelligence market research report provides valuable market insights for industry stakeholders, investors, researchers, consultants, and business strategists aiming to understand the geospatial artificial intelligence market thoroughly. Request for Free Sample to get a glance at the report now: https://www.arizton.com/market-reports/geospatial-artificial-intelligence-market

What Key Findings Will Our Research Analysis Reveal?     

How big is the global geospatial artificial intelligence market?

What is the growth rate of the global geospatial artificial intelligence market?

Who are the key players in the global geospatial artificial intelligence market?

What are the significant trends in the geospatial artificial intelligence market?

Which region dominates the global geospatial artificial intelligence market share?

Other Related Reports that Might be of Your Business Requirement     

Generative AI in Software Development Market – Global Outlook & Forecast 2025 – 2030

https://www.arizton.com/market-reports/generative-ai-in-software-development-market

Global AI In Healthcare Market – Focused Insight 2024-2029

https://www.arizton.com/market-reports/healthcare-artificial-intelligence-market

Why Arizton?                                                

100% Customer Satisfaction                                                

24×7 availability – we are always there when you need us                                                

200+ Fortune 500 Companies trust Arizton’s report                                                

80% of our reports are exclusive and first in the industry                                                

100% more data and analysis                                                

1500+ reports published till date                              

Post-Purchase Benefit                                            

1hr of free analyst discussion                                            
10% off on customization

About Us:                                                                                     

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Geospatial Artificial Intelligence Market Revenue Expected to Double – Reaching $64.6 Billion by 2030 – Arizton

Mental Wellness Market Revenue to Surge $256 Billion by 2030 – Major Giants Amare Global, FranklinCovey, Headspace, & SkillPath Transforming the Market Demand – Arizton

“Mental Wellness Market Research Report by Arizton”

According to Arizton’s latest research report, mental wellness market is growing at a CAGR of 7.45% during 2024-2030.

Looking for More Information? Click: https://www.arizton.com/market-reports/mental-wellness-market

Report Scope:           

Market Size (2030): $256.04 Billion     

Market Size (2024): $166.35 Billion     

CAGR (2024-2030): 7.45%     

Historic Year: 2021-2023     

Base Year: 2024     

Forecast Year: 2025-2030     

Market Segmentation: Disorder, Type, Age Group, and Geography

Geographical Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa     

The global mental wellness market is on a steady rise. With more people facing issues like anxiety, depression, and stress – there’s a growing demand for solutions that support mental well-being.

In 2024, the market saw strong growth as individuals turned to wellness activities, products, and services to cope with stress and mental health challenges. North America currently leads the market, making up over half of the global revenue, and is also growing the fastest. Asia-Pacific (APAC) and Europe follow closely behind.

One of the biggest trends is the rise of at-home mental wellness options, made possible through tech platforms. People now have easy access to relaxation tools like guided meditation, self-help groups, aromatherapy, brain health supplements, white noise machines, weighted blankets, and more aimed at reducing stress and promoting well-being.

Among different mental health conditions, depression tops the chart, accounting for nearly 29% of the market and growing steadily. When it comes to the types of wellness products and services people are using, those related to senses, sleep, and relaxation (like calming environments or sleep aids) are most popular. However, meditation and mindfulness tools are growing the fastest.

Adults make up the largest age group using these services, with nearly half of the market share, and they’re also the fastest-growing segment.

Overall, the mental wellness market is thriving as more people prioritize their mental health and look for accessible, effective ways to support it, especially from the comfort of home.

How AI is Transforming Mental Wellness and Therapy

Mental wellness is entering a new era, thanks to artificial intelligence (AI), which is helping deliver personalized care and education like never before. By analyzing individual behaviors, habits, and personality traits, AI can guide people toward healthier choices, making wellness programs more effective without needing as many human resources as possible.

AI is also helping reduce dropout rates from wellness programs by making them more engaging and easier to use. It allows users to track their health trends, predict future risks, and create personalized action plans to stay ahead of potential issues.

One major improvement is through chatbots, which are becoming more common on mobile devices. These AI tools provide quick, around-the-clock support for things like fitness, nutrition, and even mental health check-ins—no need for a human coach. By making wellness more accessible and interactive, AI is increasing participation, especially in employee wellness programs.

AI also collects user data through digital forms and uses it to deliver customized guidance. This includes everything from lifestyle tips to mental health strategies, all tailored to someone’s unique needs and goals.

The demand for mental health support has surged since the pandemic, especially for anxiety treatment. In response, therapists and clinics are using AI to not only personalize treatment but also improve their own practices. Tools like natural language processing (NLP) are being used to review therapy session transcripts, helping therapists better understand client conversations and continuously improve their services.

In short, AI is making mental wellness smarter, more scalable, and more personal paving the way for more effective support and better outcomes.

Depression as a Key Catalyst for Growth in the Mental Wellness Sector

The rising prevalence of depression is significantly contributing to the growth of the mental wellness market. As depression becomes a leading cause of disability globally, the demand for mental health support, treatments, and wellness solutions is growing rapidly. People are seeking accessible mental health tools, such as therapy apps, wellness programs, and digital solutions, to manage and alleviate symptoms. Increased awareness, coupled with the push for more personalized and preventive care, is expanding the market, particularly in regions where mental health services are limited. This surge in demand is fueling innovation and investment in mental wellness solutions worldwide.

North America Emerges as a Key Region in the Growing Mental Wellness Market

North America continues to lead the global mental wellness market. The widespread use of smartphones improved digital infrastructure, and a growing interest in wellness apps have made mental health support more accessible than ever before.

The U.S. and Canada are key players in this growth, as rising stress levels, lifestyle-related health issues, and growing concerns around mental health—especially among youth and older adults—drive demand for innovative solutions. Mental health conditions such as depression, anxiety, and substance use are becoming more common, prompting individuals, healthcare providers, and governments to act.

At the same time, North America remains a hub for research and innovation. Investment in new technologies like AI-driven chatbots and virtual reality therapy is making mental wellness support more engaging and personalized. There’s also a growing focus on youth mental health, with schools and universities offering more digital resources and counseling services.

Looking forward, the region is embracing more personalized and preventive care through wearable devices and mental health tracking tools. Employers are also playing a bigger role by integrating mental wellness into workplace benefits, recognizing its impact on productivity and overall employee well-being.

All these factors combined are setting the stage for strong and sustained growth in North America’s mental wellness market.

Looking for More Information? Click: https://www.arizton.com/market-reports/mental-wellness-market

Mental Wellness Market Companies

Amare Global
FranklinCovey
Headspace
SkillPath
Acadia Healthcare
Aduro
American Well Corporation
Behavioral Health Network
BHS
Calm
Calmerry
Canopy
CuraLinc Healthcare
CVS Health
DarioHealth
First Stop Health
HealthCheck360
Learn to Live
LifeSpeak
Litesprite
Lyra Health
Magellan Health
Modern Health
Pelago
Promises Behavioral Health
Pyramid Healthcare
Spire Healthcare
Spring Health
Talkspace
Universal Health Services
Unmind
Uprise Health
Vitality
Wellsource

Market Segmentation

Disorder

Depression
Anxiety
Schizophrenia
Substance Use Disorder
Bipolar Disorder
Alcohol Use Disorder
Post-Traumatic Stress Disorder
Eating Disorder
Others

Type

Senses, Spaces, and Sleep
Brain-Boosting Nutraceuticals & Botanicals
Self-Improvement
Meditation and Mindfulness

Age Group

Adult
Geriatric
Teenager

Geography

North America

The U.S.
Canada

APAC

China
Japan
South Korea
Australia
India

Europe

Germany
The U.K.
Italy
France
Spain
Russia
Netherlands

Latin America

Brazil
Mexico
Argentina
Colombia

Middle East & Africa

Turkey
South Africa
Saudi Arabia
UAE

The Arizton Advisory & Intelligence market research report provides valuable market insights for industry stakeholders, investors, researchers, consultants, and business strategists aiming to gain a thorough understanding of the mental wellness market. Request for Free Sample to get a glance of the report now: https://www.arizton.com/market-reports/mental-wellness-market

What Key Findings Will Our Research Analysis Reveal?         

What is the growth rate of the global mental wellness market?

Which region dominates the global mental wellness market share?

How big is the global mental wellness market?

Who are the key players in the global mental wellness market?

What are the significant trends in the mental wellness industry?

Other Related Reports that Might be of Your Business Requirement     

Financial Wellness Benefits Market in the United States – Research Report 2020-2029

https://www.arizton.com/market-reports/financial-wellness-benefits-market-in-united-states

U.S. Corporate Wellness Market – Industry Outlook & Forecast 2024-2029

https://www.arizton.com/market-reports/us-corporate-wellness-market-analysis-2024

Why Arizton?    

100% Customer Satisfaction                                                    

24×7 availability – we are always there when you need us                                                    

200+ Fortune 500 Companies trust Arizton’s report                                                    

80% of our reports are exclusive and first in the industry                                                    

100% more data and analysis                                                    

1500+ reports published till date                                  

Post-Purchase Benefit                                                

1hr of free analyst discussion           
10% off on customization

About Us:                                                                                         

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mental Wellness Market Revenue to Surge $256 Billion by 2030 – Major Giants Amare Global, FranklinCovey, Headspace, & SkillPath Transforming the Market Demand – Arizton

South Korea Data Center Market 2030 – Investment to Hit $9.90 Billion in the Next 6 Years – Arizton

“South Korea Data Center Market Research Report by Arizton”

According to Arizton’s latest research report, South Korea data center market is growing at a CAGR of 12.07% during 2024-2030.

To Know More, Click: https://www.arizton.com/market-reports/south-korea-data-center-market-investment-analysis

Report Summary       

Market Size – Investment (2030): $9.90 Billion       

Market Size – Area (2030): 759 Thousand Sq. ft.     

Market Size – Power Capacity (2030): 162 MW      

CAGR – Investment (2024-2030): 12.07%        

Colocation Market Size – Revenue (2030): $1.79 Billion   

Historic Year: 2021-2023       

Base Year: 2024       

Forecast Year: 2025-2030       

South Korea Growing Data Center Investment Landscape

South Korea has emerged as a key player in the APAC region for data center investments, driven by its strategic location, government support, and ample land availability. The country accounts for over 50% of the region’s data center investments, fueled by the rise of AI, IoT, big data, and cloud adoption. Efforts by the government to attract data centers outside Seoul, offering incentives like power subsidies, are addressing high demand and rising land costs in urban areas.

South Korea’s strong digital infrastructure is bolstered by its 12 existing undersea cables, connecting to global markets. Major cloud providers like AWS, Microsoft, and Alibaba are active in the region, with new data centers launching regularly. Notable recent developments include SK Telecom’s expansion of its AI-ready data center, SkyLab’s XR cloud partnership, and LS Electric’s collaboration for an AI-powered data center. Additionally, substantial investments, such as a $700 million joint venture for a hyperscale center, highlight the country’s growing prominence in the global data center market.

South Korea Colocation Data Center Market Growth

South Korea is a leading colocation data center hub in the APAC region, with over 43 operational facilities, primarily concentrated in Seoul, which houses more than 20 centers. Major global and local players, such as Equinix, Digital Realty, Telehouse, LG CNS, and KT Cloud, dominate the market. In December 2024, Digital Realty’s operational center in Seoul generated an annualized rent of $4.6 million. The revenue per MW in South Korea is estimated to range from $1.5 million to $2.0 million.

The colocation market is driven by large cloud and IT enterprises, as well as telecom hyperscale operators. New entrants, including OneAsia Network, ST Telemedia Global Data Centres, and others, are expected to boost market competition and revenue. Additionally, significant investments from real estate and investment firms, such as Macquarie Asset Management’s acquisition of Hanam Data Centre, highlight the growing interest in South Korea’s data center sector. Several major hyperscale projects are also in the pipeline, indicating strong market growth in the forecast period.

Why Should You Buy this Research?

This research provides a comprehensive analysis of the South Korea data center market, highlighting key metrics like market size, power capacity, and revenue from the colocation sector. It evaluates data center investments by colocation, hyperscale, and enterprise operators, including square footage and power capacity (MW) across various cities. The study covers existing facilities (43) and upcoming ones (13) in over 12 cities, providing insights into the growth trajectory of data center space and IT load capacity. Forecasts for the colocation market revenue (2021-2030), along with retail and wholesale colocation market analysis, are presented. It also delves into market classifications such as IT, power, cooling, and construction services. A detailed overview of key players, industry trends, growth opportunities, challenges, and a transparent research methodology is included, offering an in-depth understanding of the market’s future prospect.

Buy this Research @ https://www.arizton.com/market-reports/south-korea-data-center-market-investment-analysis

The Report Includes the Investment in the Following Areas:

IT Infrastructure

Servers
Storage Systems
Network Infrastructure

Electrical Infrastructure

UPS Systems
Generators
Transfer Switches & Switchgears
PDUs
Other Electrical Infrastructure

Mechanical Infrastructure

Cooling Systems
Rack Cabinets
Other Mechanical Infrastructure

Cooling Systems

CRAC & CRAH Units
Chiller Units
Cooling Towers, Condensers & Dry Coolers
Other Cooling Units

General Construction

Core & Shell Development
Installation & Commissioning Services
Engineering & Building Design
Fire Detection & Suppression Systems
Physical Security
Data Center Infrastructure Management (DCIM)

Tier Standard

Tier I & Tier II
Tier III
Tier IV

Geography

Seoul
Other Cities

Vendor Landscape

IT Infrastructure Providers

Arista Networks
Atos
Cisco Systems
Dell Technologies
Fujitsu
Hewlett Packard Enterprise
IBM
Inspur
Intel
Lenovo
NetApp

Data Center Construction Contractors & Sub-Contractors

BEHIVE Architects
DPR Construction
GS E&C
HanmiGlobal
Heerim Architects & Planners
Hyundai Engineering & Construction
ISG
POSCO DX
SAMOO Architects & Engineers
Samsung C&T
Shinhan Architects & Engineers

Support Infrastructure Providers

ABB
Caterpillar
Cummins
Delta Electronics
Eaton
Fuji Electric
Legrand
Mitsubishi Electric
Piller Power Systems
Rittal
Rolls-Royce
Schneider Electric
STULZ
Vertiv

Data Center Investors

Digital Edge
Digital Realty
Dreammark1
Epoch Digital
Equinix
Hostway IDC
KT Corp
LG CNS
LG Uplus
Microsoft
SK Broadband

New Entrants

Empyrion Digital
DCI Data Centers
Macquarie Asset Management
OneAsia Network
ST Telemedia Global Data Centres
STACK Infrastructure

Key Questions Answered in the Report:       

How big is the South Korea data center market?

How many existing and upcoming data center facilities exist in South Korea?

How much MW of power capacity will be added across South Korea during 2025-2030?

What is the growth rate of the South Korea data center market?

Who are the key investors in the South Korea data center market?

What factors are driving the South Korea data center market?

Why Arizton?       

100% Customer Satisfaction       

24×7 availability – we are always there when you need us       

200+ Fortune 500 Companies trust Arizton’s report       

80% of our reports are exclusive and first in the industry       

100% more data and analysis        

1500+ reports published till date       

Post-Purchase Benefit       

1hr of free analyst discussion       
10% off on customization

About Us:       

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: South Korea Data Center Market 2030 – Investment to Hit $9.90 Billion in the Next 6 Years – Arizton